RESEARCH RECORD
Selank Research: Mechanism, Trials, and the Russian Literature
Twenty-one indexed citations. One controlled human trial. Three converging mechanistic pathways. The full reading, cited.
How Selank acts in the body
Selank research converges on three mechanistic lanes, each independently documented, each insufficient alone to explain the full anxiolytic profile.
The first lane is enkephalinase inhibition. Selank inhibits plasma carboxypeptidases and dipeptidylcarboxypeptidases that degrade leu-enkephalin, with an IC50 around 20 microM — more potent than puromycin or bacitracin in the same assay [2]. The downstream consequence is a measurable extension of endogenous enkephalin signaling. Selank's anxiolytic effect tracks this enzymology with unusual fidelity: BALB/c mice (high baseline enkephalinase) respond to 100 microg/kg in the open field; C57Bl/6 mice (low baseline enkephalinase) do not [3].
The second lane is GABAA modulation. Selank potentiated diazepam's anxiolytic effect in the rat unpredictable chronic mild stress model — additive over diazepam alone — supporting functional coupling with benzodiazepine-sensitive GABAA signaling [7]. In IMR-32 cells, Selank alone produced no significant transcriptional change across 84 GABA-related genes, leading the authors to propose allosteric receptor action rather than gene-expression regulation [6].
The third lane is BDNF up-regulation. Intranasal Selank at 250 and 500 microg/kg raised hippocampal BDNF mRNA at three hours and BDNF protein at twenty-four hours in rats [4]. In a follow-on, 0.3 mg/kg/day IP for seven days normalized BDNF disturbances in hippocampus and prefrontal cortex of ethanol-impaired rats and protected cognitive performance [5].
MECHANISM
Mechanism
Beyond the three principal lanes, Selank's mechanism extends into the monoaminergic and immune systems.
In PCPA-pretreated rats (tryptophan-hydroxylase inhibited), Selank enhanced brain-stem 5-HT metabolism within thirty minutes — and tuftsin, the parent tetrapeptide, did not [8]. Selank at 0.3 mg/kg raised hypothalamic noradrenaline in both BALB/c and C57Bl/6 mice and shifted dopamine and serotonin metabolite ratios across brain regions [9]. The DSP-4 noradrenergic-lesion rat model showed Selank restoring learning and memory performance disturbed by the lesion [15].
Naloxone blocked Selank's depriming effect on apomorphine-induced behavior in rats, providing direct pharmacological evidence that the molecule's behavioral profile depends on intact opioid signaling [21]. That finding ties the enkephalinase-inhibition mechanism (lane one) to the downstream behavioral readout.
EVIDENCE SUMMARY
Evidence summary
Multiple Russian-literature randomized trials report anxiolytic effects vs placebo and comparable efficacy to medazepam in generalized anxiety cohorts [1]. The Zozulia (2008) trial is the most-cited: 62 patients, fourteen days, intranasal Selank vs oral medazepam, Hamilton/Zung/CGI improvements comparable across arms, plus an antiasthenic and psychostimulant signature medazepam did not produce.
The immunomodulatory record adds clinical depth without overclaim. A second 14-day intranasal Selank course shifted Th1/Th2 cytokine balance in patients with anxiety-asthenic disorders [10]. Under chronic social-stress conditions in rats, Selank decreased IL-1beta, IL-6, TNF-alpha, and TGF-beta1 and restored IL-4 [recent_2]. In an experimental influenza model, Selank reduced pathology and induced IFN-alpha gene expression without affecting IL-4, IL-10, or TNF-alpha [11].
The withdrawal and addiction literature is smaller but consistent. Selank attenuated aversive signs of morphine withdrawal in rats [12], reduced anxiety- and depression-like behavior in an alcohol-withdrawal model with stable alcoholic motivation [13], and blunted ethanol-induced hyperlocomotion and behavioral sensitization in DBA/2 mice [14].
Paradoxical responses reported
Trial reports describe Selank as anxiolytic across rodent and human protocols, but the dose-response curve is not flat. In WAG/Rij and Wistar rats and BALB/c mice, single low doses (100 and 300 microg/kg IP) reduced immobility in the forced-swim test; the antidepressant-like effect was lost at 600-900 microg/kg [17]. That inverted U is consistent with what the strain-dependence data shows: Selank's effect size depends on baseline enzyme activity, on genotype, and on dose. Isolated paradoxical reports exist in user forums; the controlled literature does not document an anxiogenic signal.
SAFETY
Safety
Russian trials report a benign short-term safety profile across 7-14 day courses [1][10]. Long-term human safety data — beyond a few weeks — is absent from the published literature. Russian product labeling lists pregnancy and known peptide allergy as contraindications. Outside the Russian Federation, Selank is not approved for human use in any jurisdiction.
Vendor and forum claims (hair loss, sleep effects, brain-fog reversal) frequently outrun the published evidence. Many such claims have no corresponding trial data. The honest read is that Selank has a short controlled-trial human record, a substantial preclinical mechanistic record, and a long absence of Western long-term safety studies.